TRPC3 and atrial fibrillation: In the canine model, pyrazole-3, a TRPC3 inhibitor, prolonged the ERP, decreased fibroblast proliferation and the expression of extracellular matrix-related genes, along with a reduction in AF duration [128] (Table 1).